Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The investigators will seek to determine the safety and efficacy of high-dose amiodarone
(2000mg), given as a single uniform oral dose, for the treatment of acute atrial fibrillation
in both a hospital inpatient and ambulatory outpatient setting. The investigators will
conduct a placebo-controlled randomized trial, with outcome ascertainment at 48h.